Erratum: Pneumonitis in patients treated with anti-programmed death-1/ programmed death ligand 1 therapy (Journal of Clinical Oncology (2017) 35 (709-717) DOI: 10.1200/JCO.2016.68.2005);Pneumonitis in patients treated with anti-programmed death-1/programmed death ligand 1 therapy

Journal of Clinical Oncology

Volumn 35, Issue 7, 2017, Pages 709-717

  Naidoo, Jarushka ^a,c   Wang, Xuan ^a,d,f   Woo, Kaitlin M ^a,f   Iyriboz, Tunc ^a,f   Halpenny, Darragh ^a   Cunningham, Jane ^a,b   Chaft, Jamie E ^a,b   Segal, Neil H ^a,b   Callahan, Margaret K ^a,b   Lesokhin, Alexander M ^a,b   Rosenberg, Jonathan ^a,b   Voss, Martin H ^a,f   Rudin, Charles M ^a,b   Rizvi, Hira ^a,b   Hou, Xue ^a,e   Rodriguez, Katherine ^a,b   Albano, Melanie ^a   Gordon, Ruth Ann ^a,b   Leduc, Charles ^a,f   Rekhtman, Natasha ^a,b   Harris, Bianca ^a,f   Menzies, Alexander M ^a,b,g   Guminski, Alexander D ^a,g   Carlino, Matteo S ^a,b,h   Kong, Benjamin Y ^a,f,h   Wolchok, Jedd D ^a,f   Postow, Michael A ^a   Long, Georgina V ^a   Hellmann, Matthew D ^a,b   more..

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

^c JOHNS HOPKINS UNIVERSITY   (United States)

^d PEKING UNIVERSITY CANCER HOSPITAL AND INSTITUTE   (China)

^e SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

^f UNIVERSITY OF SYDNEY   (Australia)

^g Ryde and North Shore Hospitals   (Australia)

^h BLACKTOWN HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CARBON MONOXIDE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; HEMOGLOBIN; INFLIXIMAB; MEPREDNISONE; MONOCLONAL ANTIBODY; PROGRAMMED DEATH 1 LIGAND 1; PROGRAMMED DEATH 1 LIGAND 1 ANTIBODY; UNCLASSIFIED DRUG; CARRIER PROTEIN; CD274 PROTEIN, HUMAN; CHOLINE TRANSPORTER-LIKE PROTEIN 4, HUMAN; PDCD1 PROTEIN, HUMAN; PROGRAMMED DEATH 1 RECEPTOR;

ADULT; AGED; ALLERGIC PNEUMONITIS; ANUS CARCINOMA; ARTHRITIS; ARTICLE; BLADDER CARCINOMA; BREAST CARCINOMA; BRONCHIOLITIS OBLITERANS ORGANIZING PNEUMONIA; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER PATIENT; CAUSE OF DEATH; CLINICAL FEATURE; CLINICAL OUTCOME; COLITIS; COLORECTAL CARCINOMA; CONTROLLED STUDY; CORTICOSTEROID THERAPY; DISEASE COURSE; DRUG MEGADOSE; DRUG WITHDRAWAL; DUODENITIS; ESOPHAGITIS; ESOPHAGUS CARCINOMA; FEMALE; FORCED EXPIRATORY VOLUME; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HEMATOLOGIC MALIGNANCY; HEMOLYTIC ANEMIA; HEPATITIS; HERPES SIMPLEX; HERPES SIMPLEX VIRUS 1; HUMAN; HUMAN TISSUE; HYPERTHYROIDISM; HYPOPHYSITIS; IMMUNOSUPPRESSIVE TREATMENT; INTERSTITIAL PNEUMONIA; KIDNEY CARCINOMA; LIVER CELL CARCINOMA; LUNG MYCOSIS; MAJOR CLINICAL STUDY; MALE; MELANOMA; METASTATIC MELANOMA; MONOTHERAPY; MYOSITIS; NEPHRITIS; NON SMALL CELL LUNG CANCER; OVARY CARCINOMA; PANCREAS CARCINOMA; PERNICIOUS ANEMIA; PNEUMONIA; PRIMARY TUMOR; PRIORITY JOURNAL; PROSTATE CARCINOMA; PSEUDOMONAS PNEUMONIA; RASH; RETROSPECTIVE STUDY; SARCOMA; SMALL CELL LUNG CANCER; SMOKING; STOMACH CARCINOMA; THYROIDITIS; VERY ELDERLY; VITILIGO; ADVERSE EFFECTS; ANTAGONISTS AND INHIBITORS; CHEMICALLY INDUCED; IMMUNOLOGY; IMMUNOTHERAPY; MIDDLE AGED; NEOPLASMS; PATHOLOGY; PROCEDURES; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTIGENS, CD274; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; HUMANS; IMMUNOTHERAPY; MEMBRANE TRANSPORT PROTEINS; MIDDLE AGED; NEOPLASMS; PNEUMONIA; PROGRAMMED CELL DEATH 1 RECEPTOR; TREATMENT OUTCOME;

EID: 85014010627     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2017.74.5042     Document Type: Erratum

References (37)

1. Weber JS, D'Angelo SP, Minor D, et al: Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): A randomised, controlled, open-label, phase 3 trial. Lancet Oncol 16:375-384, 2015
2. Robert C, Ribas A, Wolchok JD, et al: Antiprogrammed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: A randomised dose-comparison cohort of a phase 1 trial. Lancet 384:1109-1117, 2014
3. Brahmer J, Reckamp KL, Baas P, et al: Nivolumab versus docetaxel in advanced squamous-cell nonsmall-cell lung cancer. N Engl JMed 373:123-135, 2015
4. Borghaei H, Paz-Ares L, Horn L, et al: Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med 373:1627-1639, 2015
5. Garon EB, Rizvi NA, Hui R, et al: Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med 372:2018-2028, 2015
6. Herbst RS, Baas P, Kim DW, et al: Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): A randomised controlled trial. Lancet, 387:1540-1550, 2015
7. Motzer RJ, Escudier B, McDermott DF, et al: Nivolumab versus everolimus in advanced renal-cell carcinoma. N Engl J Med 373:1803-1813, 2015
8. Ansell SM, Lesokhin AM, Borrello I, et al: PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma. N Engl J Med 372:311-319, 2015
9. Rosenberg JE, Hoffman-Censits J, Powles T, et al: Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: A single-arm, multicentre, phase 2 trial. Lancet 387:1909-1920, 2016
10. Larkin J, Chiarion-Sileni V, Gonzalez R, et al: Combined nivolumab and ipilimumab or monotherapy in untreatedmelanoma. N Engl JMed 373:23-34, 2015
11. Le DT, Uram JN, Wang H, et al: PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med 372:2509-2520, 2015
12. Herbst RS, Soria JC, Kowanetz M, et al: Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature 515: 563-567, 2014
13. Gillison ML, Blumenschein G, Fayette J, et al: Nivolumab (nivo) vs investigator's choice (IC) for recurrent or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC): CheckMate-141. Presented at the American Association for Cancer Research Annual Meeting, New Orleans, LA, April 16-20, 2016
14. Antonia S, Goldberg SB, Balmanoukian A, et al: Safety and antitumour activity of durvalumab plus tremelimumab in non-small cell lung cancer: A multicentre, phase 1b study. Lancet Oncol 17: 299-308, 2016
15. Rizvi NA, Gettinger SN, Goldman JW, et al: Safety and efficacy of first-line nivolumab (NIVO; antiprogrammed death-1 [PD-1]) and ipilimumab in nonsmall cell lung cancer (NSCLC). Presented at the International Association for the Study of Lung Cancer Annual Meeting, Denver, CO, September 6-9, 2015
16. Weber JS, Yang JC, Atkins MB, et al: Toxicities of immunotherapy for the practitioner. J Clin Oncol 33:2092-2099, 2015
17. Postow MA: Managing immune checkpointblocking antibody side effects. Am Soc Clin Oncol Educ Book 35:76-83, 2015
18. Topalian SL, Hodi FS, Brahmer JR, et al: Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 366:2443-2454, 2012
19. Disayabutr S, Calfee CS, Collard HR, et al: Interstitial lung diseases in the hospitalized patient. BMC Med 13:245, 2015
20. Naidoo J, Page DB, Li BT, et al: Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies. Ann Oncol 26:2375-2391, 2015
21. Genestreti G, Di Battista M, Trisolini R, et al: A commentary on interstitial pneumonitis induced by docetaxel: Clinical cases and systematic review of the literature. Tumori 101:e92-e95, 2015
22. Poole BB, Hamilton LA, Brockman MM, et al: Interstitial pneumonitis from treatment with gemcitabine. Hosp Pharm 49:847-850, 2014
23. Comis RL: Bleomycin pulmonary toxicity: current status and future directions. Semin Oncol 19:64-70, 1992 (suppl 5)
24. Ando M, Okamoto I, Yamamoto N, et al: Predictive factors for interstitial lung disease, antitumor response, and survival in non-small-cell lung cancer patients treated with gefitinib. J Clin Oncol 24: 2549-2556, 2006
25. Liu V, White DA, Zakowski MF, et al: Pulmonary toxicity associated with erlotinib. Chest 132: 1042-1044, 2007
26. White DA, Camus P, Endo M, et al: Noninfectious pneumonitis after everolimus therapy for advanced renal cell carcinoma. Am J Respir Crit Care Med 182:396-403, 2010
27. Bradley J, Movsas B: Radiation pneumonitis and esophagitis in thoracic irradiation. Cancer Treat Res 128:43-64, 2006
28. Weshler Z, Breuer R, Or R, et al: Interstitial pneumonitis after total body irradiation: Effect of partial lung shielding. Br J Haematol 74:61-64, 1990
29. Palmucci S, Roccasalva F, Puglisi S, et al: Clinical and radiological features of idiopathic interstitial pneumonias (IIPs): A pictorial review. Insights Imaging 5:347-364, 2014
30. Johkoh T, Fukuoka J, Tanaka T: Rare idiopathic intestinal pneumonias (IIPs) and histologic patterns in new ATS/ERS multidisciplinary classification of the IIPs. Eur J Radiol 84:542-546, 2015
31. Kadoch MA, Cham MD, Beasley MB, et al: Idiopathic interstitial pneumonias: A radiology-pathology correlation based on the revised 2013 American Thoracic Society-European Respiratory Society classification system. Curr Probl Diagn Radiol 44:15-25, 2015
32. Comis RL: Detecting bleomycin pulmonary toxicity: A continued conundrum. J Clin Oncol 8: 765-767, 1990
33. Endo M, Johkoh T, Kimura K, et al: Imaging of gefitinib-related interstitial lung disease: Multiinstitutional analysis by the West Japan Thoracic Oncology Group. Lung Cancer 52:135-140, 2006
34. NishinoM, Sholl LM, Hodi FS, et al: Anti-PD-1-related pneumonitis during cancer immunotherapy. N Engl J Med 373:288-290, 2015
35. NishinoM, Chambers ES, Chong CR, et al: Anti-PD-1 inhibitor-related pneumonitis in non-small cell lung cancer. Cancer Immunol Res 4:289-293, 2016
36. NishinoM, Ramaiya NH, AwadMM, et al: PD-1 inhibitor-related pneumonitis in advanced cancer patients. Presented at the American Society of Clinical Oncology Annual Meeting, Chicago, IL, June 3-7, 2016
37. Gettinger SN, Zhang X, Homer R, et al: Pneumonitis in non-small cell lung cancer (NSCLC) patients treatedwith programmed death 1 (PD1) axis inhibitors. Presented at the American Society of Clinical Oncology Annual Meeting, Chicago, IL, June 3-7, 2016